Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Pagina 1 a partire dal 109 risultati
Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT.sub.6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention relates to benzofuro[3,2-c]pyridine and azepine analogs as serotonin sub-type 6 (5-HT.sub.6) modulators and uses thereof.
BACKGROUND OF THE INVENTION
Various central nervous system (CNS) disorders such as anxiety, depression, motor disorders, etc., are
Substituted 3-arylsulfonyl-pyrazolo[1,5-A]pyrimidines, serotonin 5-HT6 receptor antagonists and methods for the production and use thereof
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The invention relates to novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-HT.sub.6 receptor antagonists, active ingredients and pharmaceutical compositions, comprising the said compounds as active ingredients, method for treatment and prophylaxis of
Method of treating obesity
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention generally relates to methods of treating obesity and related disorders using inhibitors of peripheral serotonin synthesis.
BACKGROUND OF THE INVENTION
Obesity results from a chronic energy imbalance in which energy expenditure is less than energy intake.
Use of an NK-1 receptor antagonist and an SSRI for treating obesity
Solo gli utenti registrati possono tradurre articoli
Entra registrati
This invention relates to the treatment or prevention of obesity by the administration of a combination of a NK-1 receptor antagonist and a selective serotonin reuptake inhibitor.
Obesity is a chronic disease that is highly prevalent in modern society and is associated not only with a social stigma,
Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament which particularly acts on the central nervous
Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament which particularly acts on the central nervous
Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
Solo gli utenti registrati possono tradurre articoli
Entra registrati
REFERENCES OF INTEREST
Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 1996;335:609-616.
Anchors M. Fluoxetine Is a Safer Alternative to Fenfluramine in the Medical Treatment of Obesity. Arch Int Med.
Low dosage combinations of fluoxetine and reboxetine for treating obesity
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition for improved treatment of obesity. In particular, the present invention relates to compositions comprising a combination of norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors, and use
Pyrazolopyrimidine derivatives having biological activity on serotonin receptor 5-HT2c
Solo gli utenti registrati possono tradurre articoli
Entra registrati
CROSS-REFERENCE TO RELATED APPLICATION
This application claims under 35 U.S.C. .sctn.119(a) the benefit of Korean Patent Application No. 10-2009-0043728 filed May 19, 2009, the entire contents of which are incorporated herein by reference.
BACKGROUND
(a) Technical Field
The present invention relates
Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
Solo gli utenti registrati possono tradurre articoli
Entra registrati
TECHNICAL FIELD
This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are
Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
Solo gli utenti registrati possono tradurre articoli
Entra registrati
TECHNICAL FIELD
This invention relates to novel pharmaceutical compositions comprising a therapeutically effective amount of a slow-release formulation of 5-hydroxytryptophan (5-HTP) and a serotonin-enhancing compound. The pharmaceutical compositions for use according to the invention are
Substituted pyridoindoles as serotonin agonists and antagonists
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention is directed to certain novel compounds represented by structural Formula (I) ##STR2##
or pharmaceutically acceptable salt forms thereof, wherein R.sup.1, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, X, b, k, and n, and the dashed line are described
Substituted pyridoindoles as serotonin agonists and antagonists
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention is directed to certain novel compounds represented by structural Formula (D) ##STR2##
or pharmaceutically acceptable salt forms thereof, wherein R.sup.1, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, X, b, k, and n, and the dashed line are described
Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
The present invention is directed to certain novel compounds represented by structural Formula (I):
or a pharmaceutically acceptable salt thereof, wherein S.sup.ag and T.sup.ag are described herein. The invention is also concerned with pharmaceutical formulations comprising
Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION
Serotonin is a vasoconstrictor and neurotransmitter present in the brain, intestinal tissue and blood platelets. Regulation of the binding of serotonin can provide a method of treatment and prevention of a variety of illnesses including central nervous disorders,
Il database di erbe medicinali più completo supportato dalla scienza
- Funziona in 55 lingue
- Cure a base di erbe sostenute dalla scienza
- Riconoscimento delle erbe per immagine
- Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
- Leggi le pubblicazioni scientifiche relative alla tua ricerca
- Cerca le erbe medicinali in base ai loro effetti
- Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti
Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate
